Oxycodone and naloxone have an affinity for kappa, mu and delta opiate receptors in the brain, spinal cord and peripheral organs (e.g. intestine). Oxycodone acts as opioid-receptor agonist at these receptors and binds to the endogenous opioid receptors in the CNS. By contrast, naloxone is a pure antagonist acting on all types of opioid receptors. Naloxone counteracts opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N02AA55 | Oxycodone and naloxone | N Nervous system → N02 Analgesics → N02A Opioids → N02AA Natural opium alkaloids |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| TARGINACT Prolonged-release tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| TARGINACT Prolonged release tablet | Health Products Regulatory Authority (ZA) | MPI, Generic | |
| TARGIN Prolonged-release tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
